Mankind Pharma Limited
Nifty 200
Nifty 500
Midcap 50
Midcap 100
Midcap 150
LargeMid 250
F&O
₹2,502.50
+8.24%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Ind L | ₹ 1,751.20 | ₹ 4.20L Cr | 34.75 | 5.03 | 16.00 | 20.50 | 0.00 | Above FV |
| Divi S Laboratories Ltd | ₹ 9,505.50 | ₹ 2.52L Cr | 86.25 | 15.06 | 16.50 | 22.00 | 0.00 | Above FV |
| Torrent Pharmaceuticals L | ₹ 4,625.00 | ₹ 1.76L Cr | 78.13 | 9.57 | 27.40 | 15.20 | 0.00 | Above FV |
| Zydus Lifesciences Ltd | ₹ 1,172.90 | ₹ 1.17L Cr | 25.44 | 4.35 | 21.20 | 21.10 | 0.00 | Above FV |
| Cipla Ltd | ₹ 1,350.00 | ₹ 1.09L Cr | 32.37 | 3.17 | 11.60 | 15.50 | 0.00 | Above FV |
| Laurus Labs Limited | ₹ 2,142.00 | ₹ 1.16L Cr | 105.88 | 21.82 | 18.30 | 17.80 | 0.00 | Above FV |
| Dr. Reddy S Laboratories | ₹ 1,310.00 | ₹ 1.09L Cr | 39.00 | 2.83 | 11.20 | 13.00 | 0.61 | Above FV |
| Mankind Pharma Limited | ₹ 2,502.50 | ₹ 1.03L Cr | 48.46 | 6.34 | 13.10 | 13.50 | 0.00 | Above FV |
| Aurobindo Pharma Ltd | ₹ 1,627.50 | ₹ 93,643 Cr | 25.14 | 2.49 | 10.10 | 12.90 | 0.00 | Above FV |
| Lupin Limited | ₹ 1,952.00 | ₹ 89,263 Cr | 16.17 | 3.98 | 28.70 | 29.90 | 0.00 | Above FV |
| Glenmark Pharmaceuticals | ₹ 2,265.70 | ₹ 63,944 Cr | 35.57 | 6.08 | 23.60 | 39.80 | 0.11 | Above FV |
| Alkem Laboratories Ltd. | ₹ 5,078.00 | ₹ 60,715 Cr | 28.14 | 4.39 | 18.90 | 21.20 | 1.05 | Above FV |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.